Corealis Pharma and PhinC Group Collaborate to Bring Predictive Modeling into Early Formulation Development
LAVAL, Quebec -- Corealis Pharma (“Corealis”) and PhinC Group (“PhinC”) have announced a strategic collaboration to integrate physiologically based biopharmaceutics modeling (PBBM) and physiologically based pharmacokinetic (PBPK) modeling directly into oral solid dosage form development.
Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.
